Search the MBS

Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.(R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61505
• Next - Item 61524

Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61523
• Next - Item 61525

Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61524
• Next - Item 61527

Whole body study using PET, if the service is performed because the services to which items 61429, 61430, 61442, 61450 or 61453 apply cannot be performed due to the unavailability of gallium-67 (R)

Bulk bill incentive

Fee: $752.35 Benefit: 75% = $564.30 85% = $653.65

(See para IN.4.4 of explanatory notes to this Category)

• Previous - Item 61525
• Next - Item 61529

Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61527
• Next - Item 61538

FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy. (R)

Bulk bill incentive

Fee: $901.00 Benefit: 75% = $675.75 85% = $802.30

• Previous - Item 61529
• Next - Item 61541

Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R)

Bulk bill incentive

Fee: $953.00 Benefit: 75% = $714.75 85% = $854.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61538
• Next - Item 61553

Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R)

Bulk bill incentive

Fee: $999.00 Benefit: 75% = $749.25 85% = $900.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61541
• Next - Item 61559

FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery (R)

Bulk bill incentive

Fee: $918.00 Benefit: 75% = $688.50 85% = $819.30

(See para IN.0.19 of explanatory notes to this Category)

• Previous - Item 61553
• Next - Item 61560

FDG PET study of the brain, performed for the diagnosis of Alzheimer’s disease, if:

1. clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and
2. the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and
3. a service to which this item applies has not been performed on the patient in the previous 12 months; and
4. a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer’s disease

Applicable not more than 3 times per lifetime (R)

Bulk bill incentive

Fee: $605.05 Benefit: 75% = $453.80 85% = $514.30

• Previous - Item 61559
• Next - Item 61563